Aronora Inc.
Portland, OR
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1818 SW 4th Ave, Portland, OR 97201, USA
- Website
- aronora.com
- Industry
-
- Information Technology
- Software & Services
- Internet Software & Services
- SIC code
- 48 Communications
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Translational Sciences Inc. | Paradise Valley, AZ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cornovus Pharmaceuticals Inc. | New Haven, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Blood Cell Technologies LLC | Setauket- East Setauket, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
About the company
Aronora Inc. is a Portland, Oregon-based biotechnology company registered in the System for Award Management (SAM) since 2013, focusing on developing innovative pharmaceutical interventions for complex medical conditions. As a for-profit corporate entity, the company specializes in creating novel therapeutic agents targeting specific molecular pathways in blood-related and metabolic disorders. Their primary research and development efforts center on developing unique antithrombotic and anticoagulant compounds that can potentially address unmet medical needs in challenging patient populations.
The company has secured multiple federal grants from the National Heart, Lung, and Blood Institute (NHLBI) to advance specialized medical research projects. These grants include developing a contact activation-targeting antithrombotic agent (AB023/gruticibart) to prevent catheter-related thrombosis in cancer patients, investigating a thrombopoietin conjugate antisense oligonucleotide (AB062) for treating myeloproliferative neoplasms, and exploring antithrombotic approaches for end-stage renal disease patients requiring hemodialysis vascular access. Their research demonstrates a sophisticated approach to targeting specific coagulation factors like Factor XI and Factor XII, with the goal of creating safer anticoagulation strategies that minimize bleeding risks. Each grant represents a Small Business Innovation Research (SBIR) Fast Track project, indicating the company's commitment to translating innovative scientific concepts into potential medical treatments through rigorous clinical research and development processes.
Quick answers
Is Aronora Inc. registered in SAM.gov?
Yes. Aronora Inc.'s SAM.gov registration is active through September 28, 2027.
What is Aronora Inc.'s CAGE code?
Aronora Inc.'s CAGE code is 6WCC6, and its Unique Entity ID (UEI) is K57JWU3XKX95.
What is Aronora Inc.'s most recent federal award?
Aronora Inc.'s most recent federal grant award is Contact pathway inhibitor to prevent catheter-related thrombosis (R44HL170881), from National Heart Lung and Blood Institute (NIH), on June 15, 2024.
On GovTribe
See Aronora Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors